Cardiovascular comorbidities in antiphospholipid syndrome

Expert Review of Clinical Immunology

Volumn 9, Issue 10, 2013, Pages 987-990

  Muniz Caldas, Cezar A ^a,b   De Carvalho, Jozélio Freire ^c  

^a FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^b CENTRO UNIVERSITÁRIO DO ESTADO DO PARÁ   (Brazil)

^c Hospital Alianca   (Brazil)

Author keywords

antiphospholipid syndrome; benzathine benzylpenicillin; cardiovascular; metabolic syndrome; prognosis; vitamin D

Indexed keywords

BENZATHINE PENICILLIN;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; HEART INFARCTION; METABOLIC SYNDROME X; PROGNOSIS; REVIEW; VEIN THROMBOSIS; VITAMIN D DEFICIENCY;

ANIMALS; ANTIPHOSPHOLIPID SYNDROME; CARDIOVASCULAR DISEASES; COMORBIDITY; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 84886921716     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2013.837261     Document Type: Review

References (41)

1. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4, 295-306 (2006).
2. Khamashta MA, Bertolaccini ML, ØstensenM. Antiphospholipid syndrome. In: Eular Compendium on Rheumatic Diseases. Bijlsma JWJ(Ed.). BMJ Publishing Group Ltd, London, UK, 280-289 (2009).
3. Espinosa G, Cervera R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat. Rev. Rheumatol. 6(5), 296-300 (2010).
4. Shoenfeld Y, Gerli R, Doria A et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21), 3337-3347 (2005).
5. Tufano A, Guida A, Di Minno MN et al. Cardiovascular events in patients with antiphospholipid antibodies: strategies of prevention. Nutr. Metab. Cardiovasc. Dis. 20(4), 217-223 (2010).
6. Cuadrado MJ, Lopez-Pedrera C. Antiphospholipid syndrome. Clin. Exp. Med. 3, 129-139 (2003).
7. George J, Harats D, Gilburd B et al. Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 102(15), 1822-1827 (2000).
8. Shoenfeld Y, Gerli R, Doria A et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21), 3337-3347 (2005).
9. Medina G, Casaos D, Jara LJ, et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann. Rheum. Dis. 62, 607-610 (2003).
10. Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann. Rheum. Dis. 64, 315-317 (2005).
11. Soltesz P, Der H, Kerekes G, et al. A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. Clin. Rheumatol. 28(6), 655-662 (2009).
12. Cugno M, Borghi MO, Lonati LM, et al. Patients with antiphospholipid syndrome display endothelial perturbation. J.Autoimmun. 34(2), 105-110 (2010).
13. Giron-Gonzales JA, Garcia del Rio E, Rodriguez C, Rodriguez-Martorell J, Serrano A Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals.J. Rheumatol31, 1560-1567 (2004).
14. Caldas CA, da Mota LM, de Carvalho JF. Obesity in primary antiphospholipid syndrome is associated with worse outcome. Joint Bone Spine. 78(3), 324-325 (2011).
15. Soltesz P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients. Lupus 12, 302-307 (2003).
16. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291, 1978-1986 (2004).
17. Koh SB, Park JK, Yoon JH et al. Preliminary report: a serious link between adiponectin levels and metabolic syndrome in a Korean nondiabetic population. Metabolism 59, 333-337 (2010).
18. Ames PR, Antinolfi I, Ciampa A et al. Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease? Rheumatology (Oxford) 47(12), 1832-1837 (2008).
19. Rodrigues CE, Vendramini MB, Bueno C, Bonfa E, de Carvalho JF. Adipocytokines in primary antiphospholipid syndrome: potential markers of low-grade inflammation, insulin resistance and metabolic syndrome. Clin. Exp. Rheumatol. 30(6), 871-878 (2012).
20. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366(9491), 1059-1062 (2005).
21. Rodrigues CE, Bonfa E, Caleiro MT, Vendramini MB, Bueno C, Lopes JB, de Carvalho JF. Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome. Arthritis Care. Res. (Hoboken) 64(10), 1576-1583 (2012).
22. Medina G, Gutierrez-Moreno AL, Vera-Lastra O, Saavedra MA, Jara LJ. Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun. Rev 10(4), 214-217 (2011).
23. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. WHO, Geneva, Switzerland (1999).
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285(19), 2486-2497 (2001).
25. Cortez-Dias N, Martins S, Belo A, Fiuza M. Comparison of definitions of metabolic syndrome in relation to risk for coronary artery disease and stroke. Rev. Port. Cardiol 30(2), 139-169 (2011).
26. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am. J. Cardiol 96(4A), 53E-59E (2005).
27. Grundy SM, Cleeman JI, Daniels SR et al Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17), 2735-2752 (2005).
28. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet. Med. 16(5), 442-443 (1999).
29. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9(3), 237-252 (2003).
30. Vinluan CM, Zreikat HH, Levy JR, Cheang KI. Comparison of different metabolic syndrome definitions and risks of incident cardiovascular events in the elderly. Metabolism 61(3), 302-309 (2012).
31. Cigolini M, Iagulli MP, Miconi V, Galiotto M, Lombardi S, Targher G. Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 29, 722-724 (2006).
32. Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117, 503-511 (2008).
33. Siadat ZD, Kiani K, Sadeghi M, Shariat AS, Farajzadegan Z, Kheirmand M. Association of vitamin D deficiency and coronary artery disease with cardiovascular risk factors. J. Res. Med. Sci 17(11), 1052-1055 (2012).
34. Gunta SS, Thadhani RI, Mak RH. The effect of vitamin D status on risk factors for cardiovascular disease. Nat. Rev. Nephrol 9(6), 337-347 (2013).
35. Muniz Caldas CA, Freire de Carvalho J. The role of environmental factors in the pathogenesis of non-organ-specific autoimmune diseases. Best Pract. Res.Clin. Rheumatol 26(1), 5-11 (2012).
36. Merlino LA, Curtis J, Mikuls TR et al. Vitamin D intake is inversely associated with rheumatoid arthritis, 2004 rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum. 50, 72-77 (2004).
37. Munger KL, Levin LI, Hollis BW et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296, 2832-2838 (2006).
38. Klack K, Carvalho JF. High frequency of vitamin D insufficiency in primary antiphospolipid syndrome. Joint Bone Spine 77(5), 489-490 (2010).
39. Paupitz JA, Freire de Carvalho J, Caparbo VF, Klack K, Pereira RM. Primary antiphospholipid syndrome in premenopausal women: low vitamin D, high fat mass and maintained bone mineral mass. Lupus 19(11), 1302-1306 (2010).
40. Andreoli L, Piantoni S, Dall'Ara F, Allegri F, Meroni PL, Tincani A. Vitamin D and antiphospholipid syndrome. Lupus 21(7), 736-740 (2012).
41. Agmon-Levin N, Blank M, Zandman-Goddard G et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann. Rheum. Dis. 70(1), 145-150 (2011).